Hepatic fibrogenesis is a consequence of hepatic stellate cells that become activated and transdifferentiate into a myofibroblastic phenotype with the ability to proliferate and synthesize large quantities of extracellular matrix components. In this process, platelet-derived growth factor (PDGF) is the most potent stimulus for hepatic stellate cell proliferation and migration, and is overexpressed during active hepatic fibrogenesis. This cytokine binds to the PDGF receptor type b, activates Ras and sequentially propagates the stimulatory signal sequentially via phosphorylation of Raf-1, MEK and the extracellular-signal regulated kinases ERK1/ERK2. Hepatic injury is associated with both increased autocrine PDGF signaling and upregulation of PDGF receptor. In this study, we report that a dominant-negative soluble PDGF-b receptor consisting of a chimeric IgG containing the extracellular portion of the PDGF receptor type b blocks HSC activation and attenuates fibrogenesis induced by ligation of the common bile duct in rats. In culture-activated hepatic stellate cells, the soluble receptor blocks phosphorylation of endogenous PDGF receptor, phosphorylation of the ERK1/EKR2 signal and reduces proliferative activities of HSC. In vivo, both the delivery of the purified soluble PDGF antagonist and the administration of adenoviruses expressing the artificial transgene were able to reduce significantly the expression of collagen and a-smooth muscle actin. Our results demonstrate that PDGF plays a critical role in the progression and initiation of experimental liver fibrogenesis, and suggest that early anti-PDGF intervention should have a therapeutical impact on the treatment of liver fibrogenesis.
Hepatic fibrosis is a proliferative disease that may be initiated by a variety of factors including chronic viral hepatitis, alcoholic abuse, drug-induced lesions, heritable metabolic alterations, or exceptional functional disorders. Following liver injury of any etiology, hepatic stellate cells (HSC) become activated and transdifferentiate into proliferative, fibrogenic, and contractile myofibroblasts (MFB). The perpetuation of the activated phenotype involves key phenotypic responses mediated by increased cytokine effects and remodeling of extracelluar matrix (ECM). 1, 2 Enhanced cytokine responses occur through multiple mechanisms; among these, increased expression of cell membrane receptors and enhanced signaling are essential. In particular, receptor tyrosine kinases, for example, receptors for platelet-derived growth factor (PDGF), which mediate many of the stellate cell's responses to cytokines, are broadly upregulated during liver injury. 3 PDGFs form a family of dimeric isoforms inducing growth stimulation, chemotaxis, cell shape changes, and intracellular signaling in HSC from mouse, rat, or humans. 3 The PDGF receptor type a (PDGFRa) is constitutively expressed in quiescent HSC, whereas PDGF receptor type b (PDGFRb) is acquired as the cells undergo myofibroblastic phenotypic changes. 4 Moreover, in liver tissue obtained from patients with chronic liver diseases, the expression of PDGF and its receptor subunits appears closely correlated to the extent of necroinflammation and fibrosis. 5 The cellular effects of PDGF isoforms are exerted through binding to two structurally related tyrosine kinase receptors. Ligand binding induces receptor dimerization and phosphorylation of tyrosine residues within the cytoplasmic domain, enabling a number of srchomology 2 (SH2) or phosphotyrosine-binding (PTB) domains to bind to the phosphorylated receptors. This induces recruitment and activation of receptor-associated proteins following sequential activation of Ras, Raf-1, MEK and in turn the extracellular-signal regulated kinases ERK1 and ERK2 (also referred to as p44 and p42), thereby initiating various signaling pathways. [6] [7] [8] Subsequently, ERKs translocate into the nucleus and phosphorylate several transcription factors triggering a proliferative response. 9 In both cultured HSC and HSC of injured liver, there is a strong activation of the ERK pathway. 10, 11 Increasing evidence indicates that the enhanced activity of PDGFR plays a pivotal role in liver fibrosis. Importantly, codistribution of PDGF with cells expressing its receptors has been clearly demonstrated after both acute and chronic liver tissue damage, 5, 12 thus confirming an active role of this growth factor in the liver tissue repair process and in the development of hepatic fibrosis. Therefore, targeting the PDGF system by drugs that inhibit the tyrosine kinase receptor, or its intracellular signal transduction pathway, is attractive for therapeutic intervention in hepatic fibrosis. Some of these components were shown to prevent cellular activation and are beneficial in experimental models of liver fibrosis. 10, [13] [14] [15] However, most of these agents will likely not be suitable for therapeutic applications in humans, because most of the main signaling pathways involved in PDGF-induced biological effects are common to other growth factors possibly acting with positive effects on other cell types within the same tissue. 3 Therefore, direct scavenging of PDGF or application of methods allowing targeting to HSC undergoing cellular activation and subsequent transdifferentiation would offer a strategy for the treatment of fibrotic liver diseases. Inspired by the overwhelming literature describing the highly beneficial impact of local or systemic expression of a dominant-negative TGF-b receptor (TbRII) resulting in the reduction of liver fibrogenesis, improved liver function, and inhibition of cellular activation, [16] [17] [18] we examined the effects of a dominant-negative soluble PDGFRb (sPDGFRb) on hepatic fibrogenesis in culture-activated HSC and in a biliary obstruction model induced by ligature of the common bile duct (BD) in rats.
Materials and methods

Cell Isolation and Culture
HSC were isolated from male Sprague-Dawley rats by the pronase-collagenase method followed by a density centrifugation on a Nycodenz gradient and cultured as described before. 19, 20 Construction of Ad5-CMV-EGFP, Ad5-CMV-sTbRII, and Ad5-CMV-sPDGFRb
The construction of the recombinant replicationdeficient reporter Ad5-CMV-EGFP expressing the enhanced green fluorescent protein (EGFP) was described previously. 21 For cloning of pDE1sp1A-CMV-sTbRII, the NcoI fragment of the plasmid pIghTbRII 22 was blunted and cloned into the EcoRI site of pDE1sp1A. 23 The extracellular domain (ECD) of rat PDGFRb was isolated by RT-PCR from total rat MFB RNA using primers 5 0 -d(CAT GGG GCT TCC AGG AGT GAT)-3 0 and 5 0 -d (GGG CAA GGA ATG  TGG GAC CAC)-3 0 , corresponding to nt138-nt158 or complementary to nt1702-nt1722 of murine PDGFRb mRNA (Access. No. NM_008809). The resulting cDNA fragment was cloned into pGEM-T Easy (Promega, Mannheim, Germany) generating vector pGEM-rPDGFRb, followed by a second amplification using primer 5 0 -d(GAA TTC GGA CAC CAT GGG GCT TCC AGG AGT GAT)-3 0 and 5 0 -d(GGA TCC ACT TAC CTG TCA AGG AAT GTG GGA CCA)-3 0 introducing novel restriction sites for EcoRI and BamHI (underlined) and a downstream 3 0 -splice donor site (in bold). Subsequently, the ECD of PDGFRb was incorporated into vector pIg harboring the Fc region of human IgG1, a CMV promoter, and SV40-polyadenylation signal. 22 Then, the B4.2 kbp-fragment containing the PDGFRb:Fc fusion (sPDGFRb), along with the CMV promoter and SV40-polyadenylation signal was transferred into the EcoRI and HindIII sites of adenoviral shuttle vector pDE1sp1A. The integrity of all cloning boundaries was verified by sequencing, and the integration of the expression cassette from vector pDE1sp1A-CMV-PDGFRb into the adenoviral backbone vector pJM17 24 was achieved by in vitro homologous recombination as described. 21 
RNA Isolation and Northern Blot Analysis
Isolation, gel electrophoresis, and Northern blot analysis of RNA was carried out as described previously. 20, 25 Hybridization probes were the 975-bp EcoRI fragment of pGEM-rCola1(I) (a kind gift from K Knoch), and the B1.6-kbp fragment of pGEM-rPDGFRb, respectively. For internal standardization, the blots were rehybridized with a cDNA specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Polymerase Chain Reaction (PCR) for sPDGFRb Expression Analysis
Total RNA (2 mg) isolated from liver samples was reverse transcribed in 20 ml using Superscript II Reverse Transcriptase (Invitrogen, Karlsruhe, Germany) and random hexamer primers according to the manufacturer's instructions. Aliquots (2 ml) of the first strand cDNA samples were subjected to standard PCR using primer 5 
SDS-PAGE and Immunoblotting
Whole cell or liver extracts were prepared as described before. [26] [27] [28] Equal amounts of proteins were resolved in NuPAGEt Tris-Glycine gels (Novex, Groningen, The Netherlands) and electroblotted onto a Protran membrane (Schleicher & Schuell, Dassel, Germany) according to standard procedures. The primary antibodies used were: a-SMA (clone asm-1 obtained from Roche, Mannheim, Germany or from Cymbos Biotech Ltd., Chandlers Ford, UK), PDGFRb (sc-432, Santa Cruz Biotech, Santa Cruz, CA, USA), p-PDGFRb (sc-12907, Santa Cruz), PDGFRb (ECD) (Ab-1#PC17, Oncogene, San Diego, CA, USA), p44/p42 (#9102, Cell Signaling Technology, Inc., New England Biolabs GmbH, Frankfurt, Germany), and phospho-p44/42 (Thr202/ Tyr204) (#9101, Cell Signaling Technology). Primary antibodies were visualized using horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Santa Cruz) and the supersignal chemiluminescent substrate (Pierce, Rockford, IL, USA).
ELISA for sPDGFRb
For quantification of sPDGFRb in rat serum, 96-well plates (C8 Maxisorp 445101, Nunc, Wiesbaden, Germany) were coated overnight at 41C in 50mM NaHCO 3 (pH 9.1) containing 5 mg/ml rabbit antihuman IgG specific for the C H 2 domain (A 0089, DAKO, Hamburg, Germany). The plates were washed three times (0.05% Tween 20, 154 mM NaCl) and blocked with 200 ml 0.5% BSA (RIA grade, Sigma, Taufkirchen, Germany) in blocking buffer (50 mM Tris pH 7.7, 150 mM NaCl) at 41C overnight. Upon washing, 100 ml diluted rat serum was applied to duplicate wells after being diluted two times with assay buffer (0.05% Tween 20 in blocking buffer). A standard curve was set using 100 ml of the purified sPDGFRb (0-100 ng/ml) in 50% pooled-rat serum. The plates were incubated for 2 h at RT followed by washing and application of 100 ml of 0.5-1 mg/ml polyclonal goat anti-mouse PDGFRb antibody (AF1042, R&D Systems, Wiesbaden, Germany) for 1 h at RT. After the next washing, 100 ml of 1:2000 diluted polyclonal horseradish peroxidase-conjugated donkey antigoat IgG antibody (sc-2056, Santa Cruz) was added, and further incubated for 1 h at RT. BM blue POD substrate solution containing 3,3 0 -5,5 0 -tetramethylbenzidine (Roche) was applied after washing and plates were incubated at RT. The reaction was interrupted after 10-30 min with 50 ml of 1 M H 2 SO 4 and absorbance was measured in a Victor Multilabor microplate reader (EG&G Wallac, Turku, Finland) at 450 nm against a reference wavelength of 690 nm.
Expression, Purification, and Sequencing of Soluble Receptors
COS-7 cells were infected with Ad5-CMV-sTbRII or Ad5-CMV-sPDGFb in DMEM supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin. After 1 day, the medium was changed (0.5% FCS) and cells were cultured for additional 48 h. Thereafter, the supernatants were taken, cleared by a highspeed centrifugation, and proteins (sTbRII or sPDGFRb) were isolated on a Hi Trap G column (Amersham Pharmacia Biotech, Freiburg, Germany) according to the instructions of the manufacturer. For protein sequencing purified samples were dialyzed extensively against deionized water and five (sPDGFRb) or six (sTbRII) aminoterminal aminoacids were sequenced by Edman degradation at TOPLAB (Martinsried, Germany).
Adenoviral Expression Technology
Purification, infection of cultured liver cells, and administration of adenoviruses to animals were performed as described previously.
21,26-28
Proliferation Assay HSC were cultured in DMEM containing 10% FCS. On the 2nd day after seeding the serum content was reduced to 0.5% FCS for 24 h and cells were stimulated with 20 ng/ml PDGF-BB (R&D) and treated with indicated concentrations of purified sPDGFRb. After a 24 h incubation period, cells were then exposed to 75 kBq/ml [6- 3 H]-thymidine (NEN Life Science Products, Dreieich, Germany) for a 24 h labeling period. Radioactivity incorporated into DNA was measured as described before. 29 
Experimental In Vivo Model of Liver Fibrogenesis
Male Sprague-Dawley rats were infected with recombinant adenoviruses (2 Â 10 10 pfu/animal), or normal saline solution via the tail vein. After 2 days the common BD was double ligated and excised under halothane anesthesia. Rats were killed after 9 days, and pieces of the livers were fixed in 4% paraformaldehyde for histological examination or were frozen immediately in liquid nitrogen and stored at À801C for protein and RNA isolation. The study as presented was approved by the local committee for care and use of laboratory animals, and was performed according to strict governmental and international guidelines on animal experimentation. For application of purified soluble receptor proteins (sTbRII, sPDGFRb), 25 mg/animal (0.1 mg/kg sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al body weight) was administered intravenously upon bile duct ligature (BDL) according to established protocols. 30 Injections into the peritoneum were repeated twice a week until the animals were killed 14 days after surgery.
Histological Examination of Liver Tissues
Sirius Red staining was performed as described previously. 31 Briefly, liver sections were deparaffinized and the slides were incubated for 1 h in a solution of saturated picric acid containing 0.1% Sirius Red 80. Stained slides were then incubated in 0.01 N HCl for 2 min and washed in running distilled water, dehydrated, mounted, and examined by light microscopy.
Immunohistochemistry
Tissue sections (1.5 mm) were treated with xylene, rehydrated with decreasing graded ethanol, and blocked against endogenous peroxidase using 3% H 2 O 2 . For a-SMA staining, the slides were treated with a monoclonal anti a-SMA (asm-1, Roche) followed by incubation with a biotinylated antimouse secondary antibody (BA-9200, Vector Laboratories, Burlingame, CA, USA). Thereafter, the secondary antibodies were complexed with an avidin-conjugated peroxidase (Vectastain ABC-Elite reagent, Vector Laboratories) and peroxidase activity was detected with diaminobenzidine (DAKO). For better documentation the tissue sections were briefly counterstained with methyl green.
Statistics
Results are presented as the mean of three independent experiments (7s.d.). Statistical analysis was performed with an unpaired Student 0 s t-test and differences were considered as significant (*) or highly significant (**) at Po0.05 or o0.01, respectively.
Results
Cloning, Expression and Purification of sPDGFRb
The spontaneous activation of HSC on plastic and the induction of fibrogenesis by ligature of the common BD are established model systems for liver fibrosis in rat. In general, cultured HSC and MFB are nearly refractory to gene transfer by physical methods but vector systems based on adenoviruses (Ad) are suitable for delivery of transgenes into this hepatic subpopulation. 21 We generated adenovirus serotype 5 (Ad5) for constitutive expression of a chimeric cDNA, termed sPDGFRb, encoding the ECD of the PDGF receptor type b fused to the IgGFc domain of human immunoglobulin. In this construct, both domains are separated by an intron of 379 bp in size (Figure 1a ). In the translated protein the ECD of PDGFRb is linked to the Fc domain via a two-amino-acid spacer. A similar construct harboring the ECD of the TGF-b receptor type II (TbRII) fused to the Fc domain was cloned previously. 32 The expression of the chimeric sPDGFRb was assessed by Northern blot and Western blot. In COS-7 cells, Ad5-CMV-sPDGFRb infection resulted in a viral dose-dependent synthesis of two mRNAs approximately 4000 and 3600 nt in length, which were compatible with the expected sizes for the mature mRNA of the PDGFRb-Fc fusion and its progenitor RNA harboring an intron of 379 nt (Figure 1b) . The synthesis of the chimeric protein product was demonstrated in Western blot using a polyclonal antibody directed against the ECD of PDGFRb (Figure 1c) . To confirm that the synthesized protein is bivalent and has the proposed antibody-like structure, sPDGFRb was purified from culture supernatants of Ad5-CMV-sPDGFRb infected COS-7 cells and subjected to SDS-PAGE under nonreducing and reducing conditions (Figure 1d, left) . In this analysis, the purified protein migrated as a dimer of approximately 250 kDa under nonreducing conditions (ÀDTT), and as a monomer with a molecular mass around 125 kDa under reducing conditions ( þ DTT). These results indicate that the infected cells secrete the PDGFRb-Fc fusion as a dimer, consistent with the predicted structure of the chimeric protein harboring two cysteine residues in the hinge region of the Fc portion able to form two intermolecular disulfide bonds between two sPDGFRb molecules. Likewise, the electrophoretic mobility of the purified sTbRII is redox-dependent (Figure 1d, right) . The precise cleavage between signal sequences and mature exported soluble receptors (sPDGFRb, sTbRII) was confirmed by amino-acid sequence analysis revealing that sPDGFRb and sTbRII were processed at MGLPGVMPASVLRGGLL LFVLLLLGPQISQG*L (sPDGFRb) and MGRGLLRGL WPLHIVLWTRIAST*I (sTbRII), respectively. The determined cleavage sites (marked by asterisks) are in agreement with the von Heijne prediction 33 and are identical to the signal sequence processing sites proposed for the endogenous proteins. 34, 35 sPDGFRb Inhibits PDGF Signaling In Vitro PDGF is the most potent stimulus for HSC proliferation and induces a marked increase in cell proliferation, as measured by 3 H-thymidine incorporation (Figure 2a, control) . Preincubation with sPDGFRb was associated with a statistically high significant inhibition of this action (Figure 2a) . We next evaluated the effect of PDGF scavenging on phosphorylation of endogenous PDGFRb. Exposure of HSC to PDGF-BB resulted in tyrosine phosphorylation of a protein of B190 kDa, compatible with the size of endogenous PDGFRb (Figure 2b ). Pretreatment with sPDGFRb prevented the phosphorylation of this band, indicating that the soluble receptor is able to interfere with early PDGF signaling. Likewise, the phosphorylation of the downstream mediators ERK1/ERK2 (p44/p42), sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al previously shown to be an absolute requirement for triggering a proliferative response, 9 was virtually abolished to background levels after pretreatment with sPDGFRb (Figure 2c ), thus again demonstrating that sPDGFRb is able to block PDGF signaling in culture-activated HSC. In contrast, incubation with PDGF was associated with the expected appearance of two bands corresponding to the phosphorylated isoforms of ERK1 (pp44) and ERK2 (pp42).
Adenoviral Expression of sPDGFRb Prevents the Progression of Hepatic Fibrosis
Hepatic fibrosis in rats can be induced by ligature of the common BD for several weeks or months resulting in morphological changes in liver tissue comparable to those seen in human biliary fibrosis. [36] [37] [38] We used this experimental model of prolonged BD obstruction for testing the influence of sPDGFRb on the early steps of ongoing liver fibrogenesis. We applied the adenoviral vehicle 2 days prior to setting of BDL, taken into account recent reports describing that the transduction efficiencies by adenoviral-mediated gene transfer are strongly reduced after liver injury. 27, 39, 40 The injection with Ad5-CMV-sPDGFRb resulted in strong hepatic expression of the transgene at the mRNA and protein levels (Figure 3 ). High amounts of sPDGFRb were detectable (41 mg/ml) in the serum at day 4 after adenoviral injection (2 days sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al after BDL surgery) and at lower levels (B100 ng/ml) at day 9 (7 days after BDL surgery) as assessed by Western blot analysis (Figure 3b , upper part) and ELISA ( Figure 3b, lower part) . To determine the impact of sPDGFRb on liver fibrogenesis, the expression and deposition of collagen type I were assessed by Sirius red staining and Northern blot analysis ( Figure 4) . The deposition and the number of collagen fibrils was significantly decreased in rats receiving Ad5-CMV-sPDGFRb, while no reduction in the degree of fibrosis was observed in animals receiving a control adenovirus (Ad5-CMV-EGFP), indicating that the prevention was specific for Ad5-CMV-sPDGFRb (Figure 4a ). The suppression of collagen type I expression was also confirmed at the transcriptional level (Figure 4b ). However, we found that in this analysis the suppression of collagen type I mRNA was less pronounced but still significant. We next examined the influence of sPDGFRb on expression of a-smooth muscle actin (a-SMA), another marker of ongoing fibrogenesis and cellular activation. In animals receiving Ad5-CMVsPDGFRb, the signals obtained in a-SMA immunostainings were markedly reduced ( Figure 5 ), again confirming that sPDGFRb is effective in preventing progression of hepatic fibrosis.
Efficacy of Purified Proteins (sPDGFRb and sTbRII) in Preventing Liver Fibrosis
In hepatology research, adenoviral delivery approaches are attractive because they mainly target the expression of transgenes into the liver. However, the expressed soluble receptors are secreted and are detectable in circulating fluids (see above). Therefore, the application as purified proteins should have the same beneficial impact on hepatic fibrogenesis as the adenoviral approach. We purified large quantities of sPDGFRb and sTbRII from the supernatant of COS-7 cells infected by respective Western blot analysis for detection of total (PDGFRb, p42, p44) and phosphorylated forms (pPDGFRb, pp42, pp44) of proteins involved in the PDGF signaling pathway. In the experiments, HSC were treated with indicated combinations of sPDGFRb and PDGF-BB and protein extracts were analyzed for expression of pPDGFRb and PDGFRb (b), or pp44/pp42 and p44/p42 (c), respectively. sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al adenoviruses and repeated our experiments using these purified protein fractions. As expected, the efficacy (eg collagen deposition and expression) of both soluble receptors was also seen when sPDGFRb or sTbRII were administered as purified proteins (Figure 6 ), indicating that the observed antifibrotic effects were not the result of adenoviral infection per se.
Discussion
HSC are essentially involved in the development and progression of hepatic fibrosis. Profibrogenic cytokines, such as TGF-b, trigger HSC activation that involves proliferation, enhanced production of ECM components, and a phenotypic transition towards MFB, including a loss of the characteristic retinoidcontaining fat droplets. 1 Consequently, local expression of a dominant-negative type II TGF-b receptor (sTbRII) in rat livers treated with dimethylnitrosamine resulted in attenuation of liver fibrosis in a model of persistent liver fibrosis. 16 Further, the beneficial impact of sTbRII was recently demonstrated to have an inhibitory effect on the activation of rat HSC in primary culture resulting from interruption of the TGF-b autocrine signaling-loop. 18 Among other polypeptide growth factors potentially involved in chronic liver inflammation, PDGF has shown to be the most potent mitogen for cultured HSC isolated from rat, mouse, or human liver 3 reflecting the most striking molecular response of HSC to injury. Of the different possible dimeric forms of PDGF, PDGF-BB functions as the strongest stimulator of HSC growth and intracellular signaling with concurrent predominant expression of PDGFreceptor b (or type b) subunits in activated HSC. 41 Importantly, codistribution of PDGF with cells expressing the relative receptor subunits has been clearly demonstrated after both acute and chronic liver tissue damage, thus confirming a functional role of PDGF in the liver tissue repair process and in the development of hepatic fibrosis. 12, 5 For these reasons, targeting the PDGF signaling is attractive for therapeutic intervention in hepatic fibrosis. We therefore constructed a transgene, encoding the ECD of the PDGF receptor type b fused to the IgG-Fc domain of human immunoglobulin and tested the impact of this soluble PDGF receptor b (sPDGFRb) on liver fibrogenesis in vitro and in vivo. The binding of PDGF to the sPDGFRb was confirmed in proliferation assays with PDGF-BB using cultureactivated HSC. In these studies, the preincubation of HSC with sPDGFRb was able to reduce PDGF-BB-induced mitogenic response of HSC. The phosphorylation of endogenous PDGFRb was abrogated in response to sPDGFRb. We also found that sPDGFRb selectively inhibited the PDGF-BBinduced postreceptor phosphorylation of p42/p44, consistent with previous findings indicating that autophosphorylation of PDGFRb is a prerequisite for PDGF downstream signaling via the Ras/ERKregulated kinase pathway, which is likely the signal involved in the mitogenic response to PDGF. 42 These findings demonstrate that the soluble receptor is an effective means to block PDGF signaling in culture-activated HSC. In order to examine the effects of the soluble receptor on hepatic fibrosis, we used the BDL model. Previous studies have demonstrated that expression of the PDGF receptor b-subunit is increased during this experimental injury induced by biliary obstruction. 4 Using this model, we showed that the adenoviral expression or direct application of sPDGFRb as purified protein significantly attenuates ongoing fibrosis as assessed by reduced expression of a-SMA and collagen. This fits well with previous studies demonstrating that inhibitors of PDGF decrease a-SMA immunoreactivity. 43 However, Figure 3 Expression of sPDGFRb in rats. (a) In order to detect sPDGFRb mRNA expression in BD ligated ( þ BDL) and nonligated rats (ÀBDL), total RNA was isolated 9 days after adenoviral infection (7 days after BDL surgery) from rat livers and subjected to RT-PCR. In this analysis, Ad5-CMV-EGFP-infected rats served as negative controls. To verify the integrity of individual cDNA, a GAPDH specific product was amplified from each sample. (b) Western blot analysis (upper panel) and quantitative ELISA (lower panel) of serum isolated from bile duct-ligated and Ad5-CMV-sPDGFRb-infected animals. Blood samples were taken at days 4 and 9 after viral infection.
sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al compared to sTbRII, the PDGF antagonist exerts an overall weaker antifibrotic effect in experimentalinduced liver injury, supporting the notion that TGF-b plays a more pivotal role in the fibroproliferative changes that occur from tissue damage. Further, the comparison of absolute expression of type I collagen mRNA and respective protein amount as assessed by Sirius red staining suggests a relatively greater reduction of collagen at the protein level after administration of sPDGFRb. This discrepancy was previously described in experiments investigating the inhibition of hepatic sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al fibrosis by sTbRII 30 and might be due to the posttranscriptional regulation of collagen expression in cultured HSC. 44 We have not yet analyzed the impact of sPDGFRb with regard to chemotaxis of HSC towards BD structures that were shown to contribute to the development of periductular fibrosis in cholestatic disorders. 45 Probably, the reduced fibrosis observed after treatment with sPDGFRb is not a direct consequence of interfering with the processes involved in controlling the synthesis of fibrogenic markers (a-SMA, collagen) per se, but may result from blockade of HSC proliferation and inhibition of chemotaxis, thereby decreasing the number of cells able to form these destructive components. This would suggest that the combined elimination of TGF-b and PDGF could further contribute to a more effective inhibition of hepatic fibrosis. The testing of this hypothesis is a major focus of future investigations in our laboratory. sPDGFRb inhibits hepatic fibrogenesis E Borkham-Kamphorst et al
In conclusion, the data presented herein provide evidence that sPDGFRb is active as an antifibrogenic protein drug able to reduce the biological effects of PDGF in ongoing fibrogenesis. Therefore, the beneficial effects of this compound make it an attractive therapeutic agent for the treatment of fibrotic liver diseases and possibly other fibrotic organ lesions as well.
